Emgality Generic Name & Formulations
Galcanezumab-gnlm 100mg/mL, 120mg/mL; soln for SC inj; preservative-free.
Calcitonin gene-related peptide (CGRP) receptor antagonist.
Single-dose prefilled pen (120mg/mL)—1, 2; Single-dose prefilled syringe—1, 2 (120mg/mL), 3 (100mg/mL)
Prophylaxis of migraine. Treatment of episodic cluster headache.
Emgality Dosage and Administration
Give by SC inj into abdomen, thigh, back of upper arm, or buttocks. Migraine: initially 240mg loading dose (given as 2 consecutive 120mg inj), followed by 120mg monthly. Cluster headache: 300mg (given as 3 consecutive 100mg inj) at the onset of the cluster period, then monthly until the end of the cluster period.
Emgality Boxed Warnings
Discontinue if serious or severe hypersensitivity reaction occurs; treat appropriately. Pregnancy. Nursing mothers.
Emgality Adverse Reactions
Inj site reactions (eg, pain, erythema, pruritus); hypersensitivity reactions.
Emgality Clinical Trials
To enroll in the pregnancy exposure registry, call (833) 464-4724 or visit www.migrainepregnancyregistry.com.
Emgality Patient Counseling